You are here
Watson licenses hormone drug candidate from Itero
Watson Pharmaceuticals Inc. said Thursday it acquired the rights to a biologic drug that could be sold as a generic version of a female infertility treatment.
Watson licensed a recombinant follicle stimulating hormone from Itero Biopharmaceuticals. Itero's product has not yet been tested on humans.
Terms of the deal were not disclosed, but the companies said it includes an upfront payment and additional payments if the drug advances through testing and regulatory review, and royalties if it reaches the market.
Watson will assume all development, manufacturing and commercial expenses.